GlobeNewswire by notified

Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera

Share

Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera

  • First patient treated at PRIMAvera clinical site in Rome, Italy
  • Follows successful implantations at clinical sites in France, Germany, the UK and the Netherlands
  • PRIMAvera on track to read-out around the end of 2023

Paris, France, September13, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD).

This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical site in Italy at the Complesso Ospedaliero San Giovanni Addolorata. The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. The study was initiated in Q4 2020 in France. Pixium Vision has since established additional clinical sites and implanted patients in Germany, the UK and the Netherlands.

"We are very pleased to have successfully implanted the first patient in Italy with the Prima System as part of the expanding PRIMAvera pivotal study," said Prof. Andrea Cusumano,co-investigator of the PRIMAvera study for Italy."We have been following the development of the Prima System since its inception and we have seen the significant promise it shows for those suffering from dry AMD, a disease for which we struggle to provide acceptable solution and hope to patients and their families.PRIMA's small size and wireless design means the implantation is a straightforward procedure which can be completed with minimal surgery.We will move ahead now with further implantations and we look forwardto adding our efforts to the clinical assessment of this innovative technology."

The PRIMAvera study design is based on the positive data generated in a French feasibility study, showing the ability of patients with dry AMD to improve visual acuity with the Prima System.

A total of 38 patients will be implanted in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 months, and the primary safety endpoint is the number and severity of device and procedure-related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with an assessment of the primary endpoints at 12 months after implantation.

The implantation of patients has been performed at five sites in France, four in Germany as well as the Moorfields Eye Hospital in the UK, the Rotterdam Eye Hospital in the Netherlands and Complesso Ospedaliero San Giovanni Addolorata in Italy. Pixium Vision anticipates recruitment will be completed by the end of 2022 leading to a read-out of the PRIMAvera study around the end of 2023.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.

For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr

Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Contacts

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations
LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

African Development Fund mobilizes $8.9 billion for Africa’s low-income countries, the highest in its 50-year history6.12.2022 21:38:00 CET | Press release

TANGIER, Morocco, Dec. 06, 2022 (GLOBE NEWSWIRE) -- After a year of intense negotiations and a difficult global economic outlook, development partners of the African Development Fund (ADF) have agreed to commit a total package of $8.9 billion to its 2023 to 2025 financing cycle. It is the largest replenishment in the history of the Fund. ADF is the concessional window of the African Development Bank Group, providing grants and soft loans to the continent’s low-income countries. The $8.9 billion replenishment package includes $8.5 billion in core ADF funding and $429 million for the newly created Climate Action Window. ADF-16 core funding represents a 14.24% increase over ADF-15 of $7.4 billion. It is a strong endorsement of the African Development Fund and its impact in tackling the continent’s multiple development needs, including recovery from the Covid-19 pandemic, the effects of climate change, fragility, debt, and economic vulnerabilities. Algeria and Morocco contributed to the Fu

Zoltek celebrates the founder’s 80th birthday6.12.2022 20:05:26 CET | Press release

Leading the carbon fiber industry on a global scale St. Louis, Missouri, USA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Zoltek Corporation, the largest global manufacturer of industrial grade carbon fiber, has recently celebrated the 80th birthday of its founder, Zsolt Rumy. Born in December 1942 in Budapest, Hungary, Mr. Rumy was a carbon fiber industry pioneer that ultimately changed the carbon fiber world. He created the first industrial-grade carbon fiber made to compete against other common building materials, and created Zoltek Corporation to drive the commercialization of carbon fibers. Mr. Rumy fled Soviet communism after the Hungarian Revolution in 1956, and arrived in the US as a 14-year old war refugee through the International Red Cross and Catholic Charities. He later graduated with a chemical engineering degree from the University of Minnesota, accepted a position with Monsanto Company and moved to St. Louis, Missouri in 1966. After several years of corporate sales and engineerin

Mandalay Resources Corporation tillkännager CEO-förändring och befordringar i ledningsgruppen6.12.2022 19:30:23 CET | Pressemelding

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag att Dominic Duffy har informerat styrelsen om sitt beslut att avgå som President och Chief Executive Officer av personliga skäl. Dominic Duffy kommer att fortsätta som CEO och hjälpa till med ledarskapsövergången fram till sin avgång i juli 2023. Han kommer också att kvarstå i styrelsen i en icke-verkställande roll efter sin avgång som CEO. Mandalays styrelse har anlitat ett rekryteringsföretag för att hitta en efterträdare till Dominic Duffy. Mandalay har även nöjet att meddela att Ryan Austerberry från och med den 15 december 2022 befordras till Chief Operating Officer. Ryan Austerberry är för närvarande General Manager vid Mandalays Costerfield-gruva och var tidigare General Manager för Mandalays andra verksamma gruva, Björkdal. Adam Self, nuvarande Mine Manager på Costerfield, ersätter Ryan Austerberry som Costerfields General Manager. Br

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy6.12.2022 19:30:00 CET | Press release

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) versus combination chemotherapy (CT)1 Kisqali plus ET demonstrated a statistically significant progression-free survival (PFS) benefit of one year compared to combination CT; data to be presented at SABCS 20221 Kisqali is a unique CDK4/6i that has consistently shown statistically significant overall survival benefit while preserving or improving quality of life across three Phase III trials in MBC, including in patients with aggressive disease1,2-13 Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epiderma

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA6.12.2022 19:00:00 CET | Press release

Negma Group has converted 80convertible bonds in Oxurion resulting in a EUR 200,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion. Leuven, BELGIUM,Boston, MA, US–December6, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 21,008,403 new ordinary shares on December 5, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group. Following completion of the capital i